Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer

被引:9
|
作者
Shan, Guangyao [1 ]
Bi, Guoshu [1 ]
Zhao, Guangyin [1 ]
Liang, Jiaqi [1 ]
Bian, Yunyi [1 ]
Zhang, Huan [2 ]
Jin, Xing [1 ]
Hu, Zhengyang [1 ]
Yao, Guangyu [1 ]
Fan, Hong [1 ]
Zhan, Cheng [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Univ Elect Sci & Technol China UESTC, Sichuan Canc Hosp & Res Inst, Sch Med, Div Thorac Surg, Chengdu, Peoples R China
关键词
Ferroptosis; Lipid metabolism; Transcription factor; Non-small cell lung cancer; AMP RESPONSE ELEMENT; PROTEIN-KINASE; PROLIFERATION; MECHANISMS; BINDING; DEATH;
D O I
10.1186/s12931-023-02567-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Ferroptosis is a type of regulated cell death characterized by iron accumulation and lipid peroxidation. The molecular mechanisms underlying ferroptosis regulation in non-small cell lung cancer (NSCLC) are poorly understood. In this study, we found that protein kinase A (PKA) inhibition enhanced ferroptosis susceptibility in NSCLC cells, as evidenced by reduced cell viability and increased lipid peroxidation. We further identified cAMP-responsive element protein 1 (CREB1), a transcription factor and a substrate of PKA, as a key regulator of ferroptosis. Knockdown of CREB1 sensitized NSCLC cells to ferroptosis inducers (FINs) and abolished the effects of PKA inhibitor and agonist, revealing the pivotal role of CREB1 in ferroptosis regulation. Using a high-throughput screening approach and subsequent validation by chromatin immunoprecipitation (ChIP) and dual-luciferase assays, we discovered that CREB1 transcriptionally activated stearoyl-CoA desaturase (SCD), an enzyme that catalyzes the conversion of saturated fatty acids to monounsaturated fatty acids. SCD conferred ferroptosis resistance by decreasing the availability of polyunsaturated fatty acids for lipid peroxidation, and its overexpression rescued the effect of CREB1 knockdown on ferroptosis in vitro. Besides, CREB1 knockdown suppressed xenograft tumor growth in the presence of Imidazole Ketone Erastin (IKE), a potent FIN, and this effect was reversed by SCD. Finally, we showed that high expression of CREB1 was associated with poor prognosis in NSCLC patients from public datasets and our institution. Collectively, this study illustrates the effect of PKA/CREB1/SCD axis in regulating ferroptosis of NSCLC, targeting this pathway may provide new strategies for treating NSCLC patients.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Targeting CREB Pathway Suppresses Small Cell Lung Cancer
    Xia, Yifeng
    Zhan, Cheng
    Feng, Mingxiang
    Leblanc, Mathias
    Ke, Eugene
    Yeddula, Narayana
    Verma, Inder M.
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 825 - 832
  • [42] Predictive modeling of drug sensitivity in non-small cell lung cancer
    McMillan, Elizabeth
    DeSevo, Christopher
    Oswald, Nathaniel
    Hanson, Jordan
    Chen, Pei-Hsuan
    Deberardinis, Ralph
    Williams, Noelle
    MacMillan, John
    Posner, Bruce
    White, Michael
    CANCER RESEARCH, 2015, 75 (22)
  • [43] Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer
    Danesi, R
    De Braud, F
    Fogli, S
    De Pas, TM
    Di Paolo, A
    Curigliano, G
    Del Tacca, M
    PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 57 - 103
  • [44] Agrimonolide Inhibits the Malignant Progression of Non-small Cell Lung Cancer and Induces Ferroptosis through the mTOR Signaling Pathway
    Zhang, Xiaoling
    Cai, Wei
    Yan, Yiguang
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (18) : 1371 - 1381
  • [45] Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway
    Zhao, Teng
    Wang, Hong-Jian
    Zhao, Wen-Wen
    Sun, Yi-Ling
    Hu, Li-Kuan
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2017, 33 (11): : 543 - 549
  • [46] Re: The Wnt Signaling Pathway in Non-Small Cell Lung Cancer
    Hubaux, Roland
    Thu, Kelsie L.
    Lam, Wan L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (08):
  • [47] Wnt signaling pathway pharmacogenetics in non-small cell lung cancer
    Stewart, D. J.
    Chang, D. W.
    Ye, Y.
    Spitz, M.
    Lu, C.
    Shu, X.
    Wampfler, J. A.
    Marks, R. S.
    Garces, Y. I.
    Yang, P.
    Wu, X.
    PHARMACOGENOMICS JOURNAL, 2014, 14 (06): : 509 - 522
  • [48] Pathway Targets to Explore in the Treatment of Non-small Cell Lung Cancer
    Weiss, Glen J.
    Kingsley, Chris
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) : 1342 - 1352
  • [49] Wnt signaling pathway pharmacogenetics in non-small cell lung cancer
    D J Stewart
    D W Chang
    Y Ye
    M Spitz
    C Lu
    X Shu
    J A Wampfler
    R S Marks
    Y I Garces
    P Yang
    X Wu
    The Pharmacogenomics Journal, 2014, 14 : 509 - 522
  • [50] Sonic hedgehog pathway expression in non-small cell lung cancer
    Savani, Malvi
    Guo, Yan
    Carbone, David P.
    Csiki, Ildiko
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (05) : 225 - 233